Search clinical trials for: Anti-CD40 Agonist Monoclonal Antibody CDX-1140

Total 1982 results

Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

Alveolar Soft Part Sarcoma

China
Jasper Therapeutics, Inc.

Recruiting

JSP191 Antibody Targeting Conditioning in SCID Patients

SCID

United States
Facet Biotech

Completed

Pilot Study in Patients With Symptomatic Steroid-Naive Asthma

Asthma

United States
Jonsson Comprehensive Cancer Center
Eli Lilly and Company; Genentech, Inc.

Active, not recruiting

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8

United States
Great Ormond Street Hospital for Children NHS Foundation...

Completed

Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia

Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloblastic Leukemia

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Kidney Medullary Carcinoma | Loss of INI 1 Protein Expression

United States
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers

Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); AstraZeneca; Juno Therapeutics, Inc.; MedImmune...

Terminated

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Advanced Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7 | Postmenopausal | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 and other conditions

United States
Blokhin's Russian Cancer Research Center

Recruiting

Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy

Melanoma

Russian Federation
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

Solid Tumor

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

Hematopoietic and Lymphoid Cell Neoplasm | Lymphoma | Leukemia | Plasma Cell Myeloma | B-Cell Non-Hodgkin Lymphoma | T-Cell Non-Hodgkin Lymphoma

United States
Bio-Thera Solutions

Active, not recruiting

Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients

Plaque Psoriasis

China
Bristol-Myers Squibb

Completed

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Melanoma | Metastases

United States, Canada, Netherlands, United Kingdom, Germany, Chile, Belgium, France, South Africa, Argentina, Brazil, Hungary, Switzerland
CytoDyn, Inc.
Amarex Clinical Research

No longer available

An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study (CD02_EA)

HIV

United States
Shanghai Henlius Biotech

Recruiting

A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

Gastric Cancer

China
National Cancer Institute (NCI)

Completed

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

Recurrent Breast Carcinoma | Invasive Breast Carcinoma | HER2/Neu Positive | Stage IV Breast Cancer AJCC v6 and v7

United States
LigaChem Biosciences, Inc.
AntibodyChem Biosciences, Inc.

Recruiting

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Advanced Solid Tumors

United States, Canada
Taizhou Hanzhong biomedical co. LTD

Active, not recruiting

Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors

Advanced Solid Tumor

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer

Colorectal Cancer

United States, Australia
GlaxoSmithKline
Juvenile Diabetes Research Foundation

Completed

Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1 (DEFEND-1)

Diabetes Mellitus, Type 1

United States, Finland, Sweden, Italy, Spain, United Kingdom, Germany, Canada, Denmark
M.D. Anderson Cancer Center

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Locally Advanced Angiosarcoma | Metastatic Angiosarcoma | Recurrent Angiosarcoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Allogeneic Hematopoietic Stem Cell Transplantation Recipient

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IV Renal Cell Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Metastatic Squamous Neck Cancer With... and other conditions

United States
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA

Non-radiographic Axial Spondyloarthritis

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Peripheral T Cell Lymphoma

China
Humanigen, Inc.

Terminated

Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis

Rheumatoid Arthritis

United States
United BioPharma

Not yet recruiting

Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

Chronic Idiopathic Urticaria
Johns Hopkins University
Massachusetts General Hospital; National Institutes of Health (NIH); National...

Terminated

Dietary Interventions in Asthma Treatment: Sprouts Study

Asthma | Allergy

United States
Cancer Institute and Hospital, Chinese Academy...
Peking University Cancer Hospital & Institute; Affiliated Cancer Hospital &... and other collaborators

Recruiting

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

Early-stage | Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type

China
Fudan University

Recruiting

Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy

Oropharyngeal Carcinoma

China
Sinocelltech Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC

Metastatic Colorectal Cancer

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

Colorectal Cancer | Metastatic Cancer

United States
University of Washington
Bayer

Terminated

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Lymphoid Leukemia

United States
National Cancer Institute (NCI)

Completed

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing

Moderate to Severe Psoriasis

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects

COVID-19; and High Infection Risk of SARS-CoV-2

China
Humanigen, Inc.

Completed

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids (KB003-04)

Moderate-to-Severe Asthma

France, United Kingdom, United States, Australia, Poland, Ukraine
CINJRegulatory
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Rallybio IPA, LLC

Not yet recruiting

Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization

Fetal and Neonatal Alloimmune Thrombocytopenia
Energenx Medical LTD.

Recruiting

Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer

NSCLC

China
Chen Xiaoping

Completed

Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling

Hepatocellular Carcinoma | Checkpoint Inhibitor | Adjuvant Immunotherapy

China
Merck KGaA, Darmstadt, Germany

Terminated

TRUST Study: Raptiva ® in Hand & Foot Psoriasis (TRUST)

Chronic Plaque Psoriasis

Austria
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy

Breast Cancer

United States
Medical University of Warsaw

Not yet recruiting

The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH

Hiv | AIDS | ART | Treatment Resistant Disorders | CD4 Deficiency | Treatment-Sensitive HIV Infection

Search clinical trials for: Anti-CD40 Agonist Monoclonal Antibody CDX-1140

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations